Perfromance Wealth Partners LLC Trims Holdings in Eli Lilly and Company $LLY

Perfromance Wealth Partners LLC reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 12.5% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 29,705 shares of the company’s stock after selling 4,262 shares during the period. Eli Lilly and Company makes up 0.7% of Perfromance Wealth Partners LLC’s investment portfolio, making the stock its 18th largest holding. Perfromance Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $23,156,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Brighton Jones LLC raised its stake in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Covestor Ltd raised its stake in shares of Eli Lilly and Company by 24.9% during the first quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after purchasing an additional 85 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Eli Lilly and Company by 25.8% during the first quarter. GAMMA Investing LLC now owns 18,000 shares of the company’s stock worth $14,866,000 after purchasing an additional 3,696 shares during the last quarter. Finally, Warner Financial Inc. lifted its holdings in shares of Eli Lilly and Company by 129.2% during the first quarter. Warner Financial Inc. now owns 1,123 shares of the company’s stock worth $927,000 after purchasing an additional 633 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 1.8%

LLY stock opened at $818.60 on Tuesday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company’s 50-day moving average price is $743.43 and its 200 day moving average price is $765.54. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The company has a market cap of $774.77 billion, a P/E ratio of 53.50, a P/E/G ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same period last year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Berenberg Bank reissued a “hold” rating and issued a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. HSBC boosted their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Leerink Partnrs downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. UBS Group lowered their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $948.06.

Insider Activity

In other news, Director Gabrielle Sulzberger purchased 117 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 4,514 shares of company stock valued at $2,894,841 in the last 90 days. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.